12.04.18
OnDosis, a Swedish life science company, and Recipharm, have entered an agreement for the formulation development of an ADHD treatment for the U.S. market.
The new ADHD treatment will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ technology which integrates oral drugs in form of micro units and individualized dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and treatment results.
Bernard Pluta, president, Development Services, said, “The global ADHD market amounts to just over 10bn USD and there is strong demand for new solutions to help better manage this condition that affects a broad patient population. We are very proud to be able to work with OnDosis on such an important project and we believe that our excellent capabilities in drug formulation using coated pellets in Pessac, France, will be very valuable assets throughout the partnership.”
“ADHD is a disease area with a significant unmet medical need. It has been confirmed in dialogue with patients and healthcare professionals that ADHD is an area which can gain significant benefits from the new treatment regimen made possible by OnDosis technology. The decision to commence development of a formulation, which will be integrated with OnDosis technology, marks an important milestone for our company and we’re delighted to be working with Recipharm on this critical development work” said Martin Olovsson, chief executive officer of OnDosis.
The new ADHD treatment will be developed by Recipharm’s Centre of Excellence in Oral Solids and will leverage OnDosis’ technology which integrates oral drugs in form of micro units and individualized dosing, in a handheld device. The advantages are simplified titration, more accurate dosing and the ability to track dosing and treatment results.
Bernard Pluta, president, Development Services, said, “The global ADHD market amounts to just over 10bn USD and there is strong demand for new solutions to help better manage this condition that affects a broad patient population. We are very proud to be able to work with OnDosis on such an important project and we believe that our excellent capabilities in drug formulation using coated pellets in Pessac, France, will be very valuable assets throughout the partnership.”
“ADHD is a disease area with a significant unmet medical need. It has been confirmed in dialogue with patients and healthcare professionals that ADHD is an area which can gain significant benefits from the new treatment regimen made possible by OnDosis technology. The decision to commence development of a formulation, which will be integrated with OnDosis technology, marks an important milestone for our company and we’re delighted to be working with Recipharm on this critical development work” said Martin Olovsson, chief executive officer of OnDosis.
